Loading…
Loading…
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments. Viking Therapeutics remains a clinical-stage player with significant potential in the high-demand obesity and metabolic disease markets.
Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high demand suggests there's room for additional players.
Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-formulation strategy could differentiate it in a crowded obesity drug market, but it faces major risks, including strong competition and safety concerns with the oral formulation.
Jupiter Topco LLC acquired a new stake in Viking Therapeutics, Inc. (NASDAQ: VKTX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 45,700 shares of the biotechnology company's stock, valued at approximately $1,783,000. Other hedge funds and other institutional investors